“Announcing the second year of their innovation programme, Wild Card, EIT Health, a network of best-in-class innovators backed by the EU, are looking to challenge talent to deliver real solutions to the healthcare market. This year, Wild Card will focus on two challenges: mental and brain health and digital biomarkers in diagnostics Read the rest of this entry »
“Alzheimer’s research is a frontier where we can dramatically improve human life—both the lives of people who have the disease and their loved ones. I’m optimistic that we can substantially alter the course of Alzheimer’s if we make progress in several key areas. One of the biggest things we could do right now is develop a reliable, affordable, and accessible diagnostic. Read the rest of this entry »
I was pleasantly surprised to see the significant range and depth of knowledge shown by the judging panel, leading to very specific and useful questions around the key challenges to build our global research platform.
In a nutshell, what is the core idea behind Sapien Labs?
The core idea is to further our understanding of the large differences between individual brains in order to manage our brain health and brain states better. Read the rest of this entry »
Even with only a brief presentation the judges immediately got the potential impact of our technology to measure and monitor brain health and began to think about other applications for us – several we had not thought about. That was fun.
In a nutshell, what is the core idea behind NeuraMetrix?
Typing Cadence is among the strongest habit we have. If the brain is attacked by a disease, the habit will begin to break – very slowly and in very small increments. Our way of measuring is so sensitive that we can pick up changes at the level of 1/100th of second – many orders of magnitude better than today’s tools.
When and how did the idea come to you?
Coming from data security, our first idea was to use typing cadence for authentication, and then were alerted to the brain health application by an outsider. Read the rest of this entry »
“Akili Interactive Labs, Inc. (“Akili”), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. Read the rest of this entry »
As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.